Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate

Phase 2Recruiting

1 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neuroendocrine Tumors

Conditions

Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site

Trial Timeline

Jul 17, 2023 → Mar 31, 2028

NCT ID

NCT05746208

About Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate

Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate is a phase 2 stage product being developed by Merck for Neuroendocrine Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05746208. Target conditions include Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site.

What happened to similar drugs?

6 of 16 similar drugs in Neuroendocrine Tumors were approved

Approved (6) Terminated (2) Active (9)

✅Everolimus (RAD001)NovartisApproved

✅Pasireotide + DiazoxideNovartisApproved

✅everolimusNovartisApproved

✅sunitinibPfizerApproved

✅lanreotide acetateIpsenApproved

✅lanreotide (Autogel formulation)IpsenApproved

🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05746208	Phase 2	Recruiting	Jul 17, 2023	Mar 31, 2028	Neuroendocrine Tumors

Competing Products

20 competing products in Neuroendocrine Tumors

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27
Lenvatinib	Eisai	Phase 2	35
Abemaciclib	Eli Lilly	Phase 2	39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.	Jiangsu Hengrui Medicine	Phase 3	47
Famitinib	Jiangsu Hengrui Medicine	Phase 2	27
68Ga-DOTATOC	Jiangsu Hengrui Medicine	Phase 3	47
Olaparib	AstraZeneca	Phase 2	27
Avelumab	Merck	Phase 1/2	32
Pembrolizumab	Merck	Phase 2	27
Pembrolizumab	Merck	Phase 2	35
Pembrolizumab Injection	Merck	Phase 2	27
Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab	Merck	Phase 1	33
Avelumab	Merck	Phase 2	35
Pembrolizumab + Lenvatinib	Merck	Phase 2	35
Avelumab	Merck	Phase 2	35
Pembrolizumab + Irinotecan + Paclitaxel	Merck	Phase 2	35
MK-0646	Merck	Phase 2	35
Lanreotide + Pembrolizumab	Merck	Phase 1/2	32